SAN FRANCISCO, May 14, 2015 /PRNewswire/ -- Adynxx, a clinical-stage pharmaceutical company developing a transformative, first-in-class platform of therapeutics to address pain at its molecular roots, today announced completion of enrollment in a Phase 2 dose-ranging
clinical study (ADYX003) of its lead product candidate, AYX1.
GSK plans to initiate a 12 week, multi-center, dose-ranging
, placebo-controlled Phase 2 study investigating safety and efficacy of various doses of GSK2586184 in SLE patients.
Sanofi-aventis recently announced that the results of the TREK dose-ranging
study for its new injectable anticoagulant, AVE5026, were presented at the 49th annual meeting of the American Society of Haematology (ASH) in Atlanta.
The Phase I/II dose-ranging
trial will take place at The Riverside Hospital in Ottawa, and will involve 50 dyslipidemic patients (patients with low HDL and high LDL).
Tokyo, Japan, Sept 6, 2005 - (JCNN) - Sosei, a Japanese biopharmaceutical company, announced on September 5 that its wholly owned UK subsidiary Arakis has started a phase IIb dose-ranging
study of AD 452, an investigational drug for the treatment of rheumatoid arthritis (RA).
MMD-213 was a Phase II, double-masked (physician and subject), dose-ranging
, multi-center study designed to evaluate the safety and efficacy of intravenous CA4P for treating subfoveal choroidal neovascularization in subjects with pathologic myopia.
NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS system for the treatment of neurological and neuropsychiatric disorders, announced today top-line findings from a Phase II dose-ranging
study in major depressive disorder (MDD) conducted at the University of California, Los Angeles (UCLA).
The ILY101 Phase 2 trial is a multi-center, randomized, dose-ranging
study of 120 patients.
Extends Prior Dose-Ranging
Evidence to Very Low Doses of PT003; Prepares for Phase 3 -
There are multiple objectives of this dose-ranging
trial, including the measurement of nasal and non-nasal symptoms, quality of life scores and standard safety assessments.
16 /PRNewswire/ -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced positive results from a recently completed dose-ranging
study conducted as part of its Phase II clinical trials of LJP 394, its drug candidate for the treatment of lupus.
The purpose of the proposed Phase IIb dose-ranging
trial is to determine the minimum efficacious dose for MCT-125 prior to commencing a pivotal Phase III trial.